Lacripep for Neurotrophic Keratitis Gets FDA Designations

Why It Matters

The designations fast‑track Lacripep’s development and could expand therapeutic options for a rare ocular disease, while offering TearSolutions a significant commercial advantage through exclusivity and reduced dosing burden.

Key Takeaways

• FDA grants orphan‑drug and fast‑track status to Lacripep.
• Phase 2 trial begins with ~54 patients dosing three times daily.
• Lacripep could become second approved therapy for neurotrophic keratitis.
• Treatment may require half the daily administrations compared with Oxervate.
• Orphan designation offers up to seven years market exclusivity.

Pulse Analysis

Neurotrophic keratitis, a rare degenerative corneal disorder caused by nerve damage, remains an underserved niche despite the 2018 approval of Oxervate. The disease’s hallmark—loss of corneal sensation—leads to persistent epithelial breakdown and potential vision loss. Oxervate’s six‑times‑daily dosing schedule poses adherence challenges, limiting its real‑world effectiveness and leaving a clear gap for more patient‑friendly solutions.

Enter Lacripep, a synthetic peptide derived from the tear‑protein lacritin. By mimicking lacritin’s regenerative properties, Lacripep stimulates corneal epithelial and sensory nerve repair while transiently activating autophagy to clear damaged cellular components. The phase 2 trial, enrolling roughly 54 participants, tests a three‑times‑daily regimen over eight weeks, followed by an open‑label extension. FDA orphan‑drug and fast‑track designations not only provide tax credits and fee waivers but also promise up to seven years of post‑approval exclusivity, underscoring the agency’s confidence in addressing an unmet medical need.

If Lacripep secures approval, it could reshape the neurotrophic keratitis market. A reduced dosing frequency may improve patient compliance and broaden adoption among ophthalmologists, while the exclusivity window offers TearSolutions a lucrative runway to recoup R&D investment. Investors will watch the trial’s safety and efficacy readouts closely, as success could signal a new paradigm for peptide‑based ocular therapeutics and encourage further innovation in rare‑disease ophthalmology.